trial

A Registry of Treatment Adherence for Patients With Schizophrenia

NCTId NCT00283517
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase — · Completed
Enrollment 2,046 (actual)
Sponsored by Janssen-Cilag Farmaceutica Ltda.
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
2,046 (actual)
Study type
Observational
Allocation
—
Model
—
Masking
—
Start
2003-09
Primary completion
—
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
Antipsychotics

Sponsors

Janssen-Cilag Farmaceutica Ltda.Lead Sponsor

Sites

0 total

Facts & assertions

3 sourced
Enrollment
2,046
Phase
NA
Status
COMPLETED
relationships
The graph out of here
drug
Antipsychotics
drug
lead_sponsor
Janssen-Cilag Farmaceutica Ltda.
company
indication
Schizophrenia
indication
Schizophrenia
indication
Psychotic Disorders
indication